Compare Summit Therapeutics Inc (SMMT) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs TJX Companies Inc — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while TJX Companies Inc trades at $154.6 (market cap $172.00B). The key difference: TJX Companies Inc is far larger — about 16.4× Summit Therapeutics Inc's market cap, and TJX Companies Inc pays a 1.23% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TJX | |
|---|---|---|
Market Cap | $10.48B | $172.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.32 | $168.41 |
52-Week Low | $13.05 | $124.53 |
Enterprise Value | $9.90B | $180.60B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
TJX trades at $155.00, up 0.4% on the day, with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported revenue of $56.36 billion in 2025 with a net income margin of 9.4%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights TJX as a beneficiary of shifting retail trends and economic uncertainty.
The outlook for TJX remains positive, driven by earnings growth, international expansion, and strong analyst support with a consensus price target of $181.80. Key risks include competitive pressures in discount retail and sensitivity to consumer spending fluctuations, but the company's robust cash flow and dividend payments provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
